Drug Use-Results Survey of KYPROLIS

Drug Use-Results Survey of KYPROLIS (all case surveillance) [relapsed or refractory multiple myeloma]

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224009

Enrollment

600

Registered

2018-07-26

Start date

2018-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

investigational material(s) Generic name etc : KYPROLIS for Intravenous Injection 10 mg, KYPROLIS for Intravenous Injection 40 mg INN of investigational material : carfilzomib Therapeutic category cod

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with relapsed or refractory multiple myeloma to whom KYPROLIS was administered

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety items : Occurrence of adverse drug reactions/infections, factors considered to influence the safety Efficacy items : Comprehensive improvement, factors considered to influence the efficacy	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026